# A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

> **NCT04969835** · PHASE1 · RECRUITING · sponsor: **Avacta Life Sciences Ltd** · enrollment: 158 (estimated)

## Conditions studied

- Salivary Gland Tumor
- Urothelial Carcinoma
- Ovarian Carcinoma
- Breast Cancer
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** AVA6000

## Key facts

- **NCT ID:** NCT04969835
- **Lead sponsor:** Avacta Life Sciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-16
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969835, "A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04969835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*